On May 18, Axinn partner Chad Landmon led a discussion on, “The Impact of the Purple Book Continuity Act on Strategies for Biosimilar Development” at the 2021 FDLI Annual Conference: Exploring Advanced Topics in Food and Drug Law. This year’s virtual conference hosted an array of experts that addressed the latest trends and updates in complex legal, regulatory, compliance, and policy issues currently impacting all facets of FDA-regulated industry.

Founded in 1949, the Food and Drug Law Institute (FDLI) is a nonprofit membership organization that offers education, training, publications, and professional engagement opportunities in the field of food and drug law.

Click here for more information.